New Alzheimer’S Drug that halts mental decline is ‘best news for dementia in 25 years’
New Alzheimer’S Drug halts mental decline In its clinical trial, this New Alzheimer’S Drug helped to erase beta amyloid, a sticky plaque that builds up in the brain and can lead to the symptoms of Alzheimer’s disease. The results of phase one of the study were reported in the journal Nature last month and included 165 patients with early stage Alzheimer’s. Patients with this level of the disease typically have trouble remembering conversations, using things around the house or concentrating, but can otherwise function on their own.
The truly devastating part of Alzheimer’s is that these symptoms almost always continue to worsen.Biogen’s phase one trial showed that those receiving the highest doses of this New Alzheimer’S Drug every month over the course of a year saw the greatest decrease in the amount of amyloid plaque in their brains. Researchers were able to view this change through the use of a high-powered imaging tool known as a brain PET (positron emission tomography) scan.